Fig. 1: Interception study design and results.

A Experimental design for the interception study. Eleven days after tumor implantation, mice were randomized to receive primary treatment for 5 days: 1) vehicle; 2) PARP inhibitor (PARPi; treatment days 1-5); or 3) PARPi (treatment days 1-5) and AKT inhibitor (AKTi; treatment days 4-5). The average tumor diameter at day 11 was between 2 to 3 mm. PARPi, olaparib, was administered daily 50 mg/kg i.p., while AKTi, capivasertib, was administered daily 120 mg/kg orally. B Cancer interception rates in the three treatment arms. C Example of necropsy images to confirm that the mice achieved complete interception of the tumor at the end of the experiment. Black arrows indicate the site of tumor implantation. D Kaplan–Meier survival curves depicting overall survival of mice across treatment groups. Tumor reaching 10 mm in the longest diameter was set as the endpoint. E The growth curves of the tumors from starting primary treatment to 10 mm endpoint, corresponding to (D). F Kaplan-Meier curves show the treatment outcome starting from 10 mm to 20 mm tumor diameter. G The growth curve of the tumors corresponding to (F).